Puma Biotechnology Beats Q2 Estimates and Lifts Full-Year Outlook on Robust NERLYNX Demand
PBYI has more than doubled off its 52-week low of $3.05.
Summary
Puma Biotechnology posted Q2 revenue of $56.5M and adjusted EPS of $0.20, exceeding estimates, and raised its full-year guidance. The company has fully repaid its debt and holds $93.9M in cash, with multiple clinical milestones for alisertib expected over the next year. Full-year 2026 net product revenue guidance was raised to $205–209M from $202–206M, and Q3 revenue is guided to $56–59M.
Updated with a Reuters report · What changed
Updates
· Reuters — Full-year 2026 net product revenue guidance was raised to $205–209M from $202–206M, and Q3 revenue is guided to $56–59M.
Key Events · Earnings and Guidance · PBYI
-
New · · Reuters
Net Product Revenue Guidance
Full-year 2026 net product revenue guidance was raised to $205–209M from $202–206M, and Q3 revenue is guided to $56–59M.
-
Updated · · Reuters
Raised Full-Year Guidance
Full-year 2026 revenue guidance was raised to $224–$231M, up from $222–$229M, and net income guidance increased to $17–$20M, up from $16–$19M.
-
Q2 Earnings Beat
Total revenue reached $56.5M—comprising $53.6M in product revenue and $2.9M in royalties—while adjusted EPS came in at $0.20, beating the single-analyst estimate of $0.04.
-
Debt-Free Balance Sheet
All debt was fully repaid in May 2026; cash, equivalents, and marketable securities totaled $93.9M at quarter-end.
-
Alisertib Pipeline Progress
Key milestones over the next 12 months include the initiation of ALISCA-Lung2 in Q3 2026, expansion of ALISCA-Breast1 and ALISCA-Lung1 in the second half of 2026, and updated ALISCA-Breast1 data in Q4 2026.
Analysis · PBYI · Life Sciences
A strong second quarter saw Puma Biotechnology deliver revenue of $56.5M and adjusted EPS of $0.20, easily surpassing the lone analyst estimate of $0.04. Confidence in sustained NERLYNX demand prompted the company to raise its full-year revenue and net income guidance. The balance sheet is now pristine after full debt repayment, leaving $93.9M in cash, while the pipeline advances toward key alisertib milestones. For a small-cap biotech, this represents clear commercial execution and a positive signal. Full-year 2026 net product revenue guidance was raised to $205–209M from $202–206M, and Q3 revenue is guided to $56–59M.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36% of the 1040 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PBYI was trading at $8.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $413.3M. The 52-week trading range was $3.05 to $8.75. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.